Zemplar and Haematemesis - a phase IV clinical study of FDA data

Summary:

Haematemesis is reported as a side effect among people who take Zemplar (paricalcitol), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Plavix, and have Hyperparathyroidism secondary.

The phase IV clinical study analyzes which people have Haematemesis when taking Zemplar. It is created by eHealthMe based on reports of 15,456 people who have side effects when taking Zemplar from the FDA, and is updated regularly.

What is Zemplar?

Zemplar has active ingredients of paricalcitol. It is often used in kidney disease. eHealthMe is studying from 15,494 Zemplar users. Check the latest studies of Zemplar.

What is Haematemesis?

Haematemesis (vomiting of blood) is found to be associated with 1,458 drugs and 2,238 conditions by eHealthMe. Check the latest studies of Haematemesis.

On Aug, 11, 2026

15,456 people reported to have side effects when taking Zemplar.
Among them, 39 people (0.25%) have Haematemesis.

Among these 39 people:

How long have people been on Zemplar when they have Haematemesis? *

What is the gender of people who have Haematemesis when taking Zemplar? *

female: 69.23 %
male: 30.77 %

What is the age of people who have Haematemesis when taking Zemplar? *

What are other drugs people take besides Zemplar? *

What are other side effects people have besides Haematemesis? *

Nausea (feeling of having an urge to vomit): 9 people, 23.08%
Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 8 people, 20.51%
Gastric Haemorrhage (bleeding stomach): 6 people, 15.38%
Nausea And Vomiting: 6 people, 15.38%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 5 people, 12.82%
Anaemia (lack of blood): 5 people, 12.82%
Malaise (a feeling of general discomfort or uneasiness): 5 people, 12.82%
Swelling: 4 people, 10.26%
Hiatal Hernia (hernia resulting from the protrusion of part of the stomach through the diaphragm): 4 people, 10.26%
High Blood Pressure: 4 people, 10.26%

What are the existing conditions these people have? *

Hyperparathyroidism Secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary): 21 people, 53.85%
Chronic Kidney Disease: 9 people, 23.08%
Hyperparathyroidism (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium): 6 people, 15.38%
Pain: 4 people, 10.26%
High Blood Pressure: 4 people, 10.26%
Stress And Anxiety: 3 people, 7.69%
Hypersensitivity: 3 people, 7.69%
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 2 people, 5.13%
Diabetes: 2 people, 5.13%
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall): 1 person, 2.56%

* Approximation only. Some reports may have incomplete information.

Do you take Zemplar and have Haematemesis?

- Check whether Haematemesis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zemplar:

Zemplar (15,494 reports)

Haematemesis treatments and more:

Haematemesis (33,968 reports)

Browse all side effects of Zemplar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Haematemesis:

Haematemesis (1,458 drugs)

Browse all the conditions that are associated with Haematemesis:

Haematemesis (2,238 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on paricalcitol (the active ingredients of Zemplar) and Zemplar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.